The collaboration will focus on precision medicine tailored to individual needs to advance the personalised medicine and genomics for the diagnosis and treatment of multiple myeloma and non-small cell lung cancer (NSCLC)
DoH signs MoU with M42 and AbbVie. (Credit: PRNewsfoto/The Department of Health - Abu Dhabi)
Abu Dhabi’s Department of Health (DoH), the healthcare regulator in the Emirate, has signed a Memorandum of Understanding (MoU) to collaborate with AbbVie and M42.
M42 is a tech-enabled, integrated healthcare company created through the combination of G42 Healthcare and Mubadala Health.
The collaboration will aim to advance precision medicine and genomics in Abu Dhabi, for the diagnosis and treatment of multiple myeloma and non-small cell lung cancer (NSCLC).
DoH intends to advance research that enhances patient access to new approaches in healthcare, contributing to policy changes and guideline implementation.
Abu Dhabi Department of Health (DoH) research and innovation centre executive director Asma Al Mannaei said: “It is with no doubt that personalised medicine and genomics hold the transformative potential to reshape the delivery of care and improve outcomes.
“Abu Dhabi continues to harness the power of these fields to unlock a new era of healthcare where every patient’s journey is guided by their own genetic blueprint, leading to enhanced quality of life and a brighter future for generations to come.”
G42 Healthcare senior director Francesco Redivo said: “Our collaboration will be built on joint efforts to advance precision medicine by harnessing real-world evidence capabilities, shaping innovative solutions around access to care and translating scientific advancements into tangible patient benefits by maximizing the potential of Emirati Genome Programme.”
Last year, Abu Dhabi introduced the region’s first Personalised Precision Medicine Programme for oncology, as part of its preventive healthcare efforts.
The programme integrates predictive, personalised, and precision medicine using genomics to transform diagnostics, drug therapy and prevention.
DoH said that the collaboration, focusing on precision medicine tailored to individual needs, will maximise the Emirate’s genomics programme and translates into patient benefits.
Abu Dhabi’s healthcare regulator defines the strategy for the health system, and monitors and analyses the health status of the population and the performance of the system.
In addition, the regulator outlines the regulatory framework, inspects, enforces the standards, and promotes best practices and performance by healthcare service providers.
AbbVie Gulf and Levant general manager Hassan Sabbah said: “This partnership aims to advance precision medicine in the diagnosis and treatment to help enable broader patient access in UAE to innovative therapies.
“Our efforts are progressing to launch several initiatives that support research and clinical trials and develop innovative solutions to deal effectively with local and regional health needs, challenges, and burdens.”